Vimta Labs

Vimta Labs achieved its highest-ever quarterly revenue of INR993 million in Q1 FY26, marking a substantial 31.4% year-on-year growth. This strong top-line performance translated into robust profitability, with EBITDA increasing by 33.1% to INR354 million, maintaining a healthy margin of 35.7%. Profit after tax (PAT) also saw a significant jump of 35.9% year-on-year, reaching INR189 million, with PAT margins at 19%. The company maintains a net debt-free balance sheet with INR379.3 million in cash and cash equivalents.

Pharmaceutical testing and research services remain a major revenue contributor, meeting management expectations. The company successfully completed an unannounced US FDA GCP inspection with no Form 483 observations and received cGMP compliance from ANSM EMA. In the food testing segment, consistent business growth is observed, supported by the establishment of a new food lab in Andhra Pradesh and the occupation of the new facility by food testing activities.

Vimta Labs is expanding into biologics contract research and development services, with equipment procurement currently underway and commercialization targeted for Q1 FY27. This strategic move aims to offer an end-to-end service package, including characterization, analytical, preclinical, clinical, and formulation development, providing a unique competitive advantage in the market. Approximately INR30 crores of the planned FY26 capex is allocated to setting up these biologics services.

The electrical and electronics testing services remained stable in Q1 FY26. Management views this as a 'sunrise industry' with significant growth potential, particularly driven by the defense and telecom sectors in the next 2-3 years. The company has already installed a second EMI/EMC chamber, indicating good utilization of existing capacities and readiness for future demand, especially as regulations continue to develop.

For FY26, Vimta Labs plans a capex outlay of approximately INR100 crores. This follows an FY25 capex of upward of INR60 crores primarily for the new facility. The FY26 capex will be used for the biologics setup (INR30 crores), new/replacement equipment, and digitization initiatives. The new facility, which houses food testing and will accommodate preclinical activities, is expected to manage the company's growth for the next half a decade.

While current EBITDA margins are strong at 35.7%, management anticipates a potential 1-2% reduction in the coming quarters^⏳. This expected compression is attributed to costs associated with new facility maintenance, lab redesigning, and increasing human resource expenses, before margins stabilize. In a move to enhance shareholder value, the Board approved a 1:1 bonus issue, reflecting confidence in the company's financial strength and future growth prospects.

Management noted that while export revenues have grown proportionately to the overall business, domestic revenue has remained flat or slightly degrown. This trend is explained by the Indian market reaching a mature level, offering fewer growth opportunities compared to overseas markets. The company emphasizes its focus on addressing the high-quality requirements of developed markets, viewing the export growth as a positive rather than the domestic trend as a negative.